Research
Research groups
Research interests
- Affordable microfluidic diagnostics and "µMicro" miniaturised microbiology
- Engineering next generation vaccines: formulation and function
Current research
With a background in fundamental immunology combined with expertise in biochemical engineering, I am an interdisciplinary researcher focussed on solving current and future healthcare challenges using an engineering science approach that combines a range of fields from biology, biochemistry, chemistry and physics. I work at the interface between academic technology discovery and industrial development and have experience of both fundamental research and the commercialisation of new technology.
The two main challenges I currently work on are the development of affordable microfluidic technology for clinical diagnostics and microbiology, and the engineering science of complex biologic therapeutics such as vaccines.
Affordable microfluidic diagnostics and "µMicro" miniaturised microbiology
A major area of research focuses on developing simple devices for portable, low-cost, point of care bioassay testing exploiting a novel melt-extruded microstructured material called Micro Capillary Film (MCF). Because the melt-extrusion manufacture process is highly scalable, MCF represents an exceptionally low cost microfluidic material.
MCF is especially suitable for performing the many and varied tests that are used to detect and identify microorganisms such as bacterial pathogens. We are therefore pioneering the miniaturisation of microbiology tests using MCF. We believe that microfluidics will become an especially important tool for analytical microbiology, a new field we term "µMicro".
Engineering next generation vaccines: formulation and function
Conventional vaccines require injection, refrigerated distribution, and challenging manufacturing processes. New vaccines against emerging infections are slow and expensive to develop. This is partly because existing vaccines are typically developed using decades-old empirical methods. I am interested in developing technologies that allow rapid, low-cost discovery and manufacture of fully engineered vaccines against emerging and existing infections.